Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Ltd (NATHBIOGEN) last traded at ₹153, a market capitalisation of ₹290 crore, on a P/E of 8.58. Over the past 52 weeks the stock has ranged between ₹126 and ₹207. Nath Bio-Genes (India) Ltd last reported results for the quarter ended Jun 2026, with sales of ₹328 crore and net profit of ₹32 crore. Figures are as of 25 Aug 2026 and are not real time.
Nath Bio-Genes (India) Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Nath Bio-Genes (India) Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹328 cr, up 15.5% from ₹284 cr a year earlier. Net profit was ₹32 cr, up 14.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 37 | 52 | 284 | 44 | 66 | 52 | 328 |
| Expenses | 27 | 29 | 52 | 254 | 38 | 62 | 47 | 293 |
| Operating profit | 5 | 8 | 0 | 29 | 6 | 4 | 4 | 35 |
| OPM % | 15% | 22% | 0.8% | 10% | 14% | 5% | 9% | 11% |
| Other income | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 3 |
| Interest | 3 | 4 | 1 | 3 | 4 | 5 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 4 | 2 | 29 | 5 | 2 | 2 | 33 |
| Tax % | -3% | 30% | 30% | 2% | 12% | 35% | 100% | 2% |
| Net profit | 1 | 3 | 1 | 28 | 5 | 2 | -0 | 32 |
| EPS (₹) | 0.58 | 1.39 | 0.78 | 14.88 | 2.54 | 0.84 | -0.01 | 16.98 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Nath Bio-Genes (India) Ltd annual results
| ₹ crore | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 109 | 230 | 234 | 248 | 268 | 445 | 490 |
| Operating profit | 20 | 37 | 49 | 50 | 51 | 52 | 49 |
| OPM % | 18% | 16% | 21% | 20% | 19% | 12% | 10% |
| Net profit | 12 | -67 | 35 | 40 | 39 | 42 | 39 |
| EPS (₹) | 7.34 | -35.46 | 18.43 | 20.85 | 20.31 | 21.91 | 20.35 |
TTM is the trailing twelve months to the most recent quarter.
Nath Bio-Genes (India) Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 24%
- TTM
- 21%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 1%
- TTM
- 9%
- 10 Years
- 4%
- 5 Years
- -13%
- 3 Years
- -10%
- 1 Year
- -12%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 6%
- Last Year
- 5%
Nath Bio-Genes (India) Ltd shareholding pattern
Promoters held 45.59% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.26% and DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% | 45.59% |
| FIIs | 0.18% | 0.19% | 0.21% | 0.41% | 0.32% | 0.31% | 0.22% | 0.26% |
| DIIs | 4.37% | 4.37% | 3.94% | 2.25% | 0.76% | 0.01% | 0.01% | 0.01% |
| Public | 49.83% | 49.83% | 50.24% | 51.73% | 53.31% | 54.08% | 54.17% | 54.13% |
| No. of shareholders | 35,423 | 35,056 | 34,911 | 34,207 | 34,122 | 33,550 | 33,031 | 32,564 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Nath Bio-Genes (India) Ltd corporate filings
- Intimation of Initiation of Forensic AuditCompany Updatemedium impact
Cruxal's analysis: The company has formally intimated the initiation of a forensic audit under Regulation 30…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Nath Bio-Genes (India) Ltd
Cruxal reads every Nath Bio-Genes (India) Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.